LifeVantage Corp
NASDAQ:LFVN
LifeVantage Corp
LifeVantage Corp. engages in the identification, research, development and distribution of advanced nutraceutical dietary supplements and personal care products. The company is headquartered in Lehi, Utah and currently employs 160 full-time employees. The company went IPO on 2012-09-12. Its products include Protandim, LifeVantage Omega+, ProBio and Daily Wellness dietary supplements, TrueScience, Axio and PhysIQ. LifeVantage Omega+ is a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and Vitamin D3 to support cognitive health, cardiovascular health, skin health, and the immune system. ProBio is a dietary supplement designed to support optimal digestion and immune system function. Daily Wellness is a dietary supplement designed to support and strengthen immune health. TrueScience, which consists of facial cleanser, perfecting lotion, eye serum. PhysIQ, which consists of fat burn, prebiotic and whey protein.
LifeVantage Corp. engages in the identification, research, development and distribution of advanced nutraceutical dietary supplements and personal care products. The company is headquartered in Lehi, Utah and currently employs 160 full-time employees. The company went IPO on 2012-09-12. Its products include Protandim, LifeVantage Omega+, ProBio and Daily Wellness dietary supplements, TrueScience, Axio and PhysIQ. LifeVantage Omega+ is a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and Vitamin D3 to support cognitive health, cardiovascular health, skin health, and the immune system. ProBio is a dietary supplement designed to support optimal digestion and immune system function. Daily Wellness is a dietary supplement designed to support and strengthen immune health. TrueScience, which consists of facial cleanser, perfecting lotion, eye serum. PhysIQ, which consists of fat burn, prebiotic and whey protein.
Revenue Decline: Revenue dropped 27.8% year-over-year to $48.9 million, mainly due to declining sales of the MindBody GLP-1 system.
Inventory Reserve: The company took a $2.4 million onetime inventory reserve related to excess MindBody GLP-1 inventory.
LoveBiome Integration: The LoveBiome acquisition contributed $4.1 million in new revenue and is driving new product launches and operational synergies.
Profitability Impacted: Gross margin fell to 74% from 80.5% last year; operating and net income also decreased sharply.
New Share Repurchase: Announced a new $60 million share repurchase program while maintaining a quarterly dividend.
CEO Transition: CEO Steve Fife announced his planned retirement in April, with a succession plan underway.
Guidance Lowered: Fiscal 2026 revenue guidance set at $185–$200 million, with adjusted EPS of $0.60–$0.80, reflecting ongoing headwinds.
